Nothing said here yet.
to join the conversation.
| Mensinger MikeChief Product Officer | Sell | 2,650 | $58.3K | Tue, Oct 27 |
| Hopman MarkChief Commercial Officer | Sell | 821 | $16.4K | Mon, Oct 26 |
| Hopman MarkChief Commercial Officer | Sell | 775 | $13.4K | Wed, Oct 14 |
| Hopman MarkChief Commercial Officer | Sell | 370 | $7.0K | Thu, Oct 1 |
| Jones ChristyDirector | Sell | 6,430 | $147.9K | Tue, Sep 22 |
| Hopman MarkChief Commercial Officer | Sell | 30,779 | $619.6K | Wed, Sep 16 |
| Mensinger MikeChief Product Officer | Sell | 2,650 | $58.3K | Wed, Sep 16 |
| Hopman MarkChief Commercial Officer | Sell | 775 | $12.0K | Mon, Sep 14 |
| Hopman MarkChief Commercial Officer | Sell | 36,870 | $680.7K | Wed, Sep 9 |
| Saint SeanPresident & CEO | Sell | 5,641 | $113.3K | Thu, Sep 3 |
| Saint SeanPresident & CEO | Sell | 16,867 | $322.4K | Wed, Sep 2 |
| Feider StephenChief Financial Officer | Sell | 6,675 | $127.6K | Wed, Sep 2 |
Moby summary of Beta Bionics, Inc.'s Q3 2026 earnings call
Revenue hit $35.5 million with 30% growth as Mint patch pump nears Q1 2027 launch.
Beta Bionics (NASDAQ:BBNX) reported third-quarter net sales of $35.5 million, up about 30% from a year earlier, as new patient starts and recurring revenue from its pharmacy-channel user base supported growth.
Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +1.89% and +0.96%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Faruqi Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages...
Beta Bionics, Inc. (BBNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Faruqi Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages...
Beta Bionics now carries an updated fair value estimate of US$23.80 per share, up from about US$21.67, which refines how analysts frame the stock’s long term potential.
BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.